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Abstract
Loss of Fhit expression, encoded at chromosome fragile site FRA3B, leads to increased replication stress, genome
instability and accumulation of genetic alterations. We have proposed that Fhit is a genome ‘caretaker’ whose loss
initiates genome instability in preneoplastic lesions. We have characterized allele copy number alterations and
expression changes observed in Fhit-deficient cells in conjunction with alterations in cellular proliferation and exome
mutations, using cells from mouse embryo fibroblasts (MEFs), mouse kidney, early and late after establishment in
culture, and in response to carcinogen treatment. Fhit-/- MEFs escape senescence to become immortal more rapidly
than Fhit+/+ MEFs; -/- MEFs and kidney cultures show allele losses and gains, while +/+ derived cells show few
genomic alterations. Striking alterations in expression of p53, p21, Mcl1 and active caspase 3 occurred in mouse
kidney -/- cells during progressive tissue culture passage. To define genomic changes associated with preneoplastic
changes in vivo, exome DNAs were sequenced for +/+ and -/- liver tissue after treatment of mice with the carcinogen,
7,12-dimethylbenz[a]anthracene, and for +/+ and -/- kidney cells treated in vitro with this carcinogen. The -/- exome
DNAs, in comparison with +/+ DNA, showed small insertions, deletions and point mutations in more genes, some
likely related to preneoplastic changes. Thus, Fhit loss provides a ‘mutator’ phenotype, a cellular environment in
which mild genome instability permits clonal expansion, through proliferative advantage and escape from apoptosis,
in response to pressures to survive.
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Introduction
In hereditary cancers, genomic instability resulting from
mutations in DNA repair genes, known as caretaker genes,
drives cancer development, but sequencing of many non-
familial cancers has not detected frequent mutations in DNA
repair genes. Thus, for sporadic cancers the molecular basis of
genomic instability is not known. A prevailing view for the
development of genome instability in sporadic cancers is that it
is due to oncogene activation at some point during cancer
development. According to this view, supported mainly by
oncogene overexpression experiments, the mutation patterns
of specific tumor suppressor genes, such as TP53, support the
oncogene-induced DNA replication stress model, which
attributes genomic instability and suppressor gene mutations to
oncogene-induced DNA damage [1].
It has been known for years that common chromosome
fragile loci, that are expressed as chromatid gaps or breaks in
blood cells of all individuals under conditions of mild replication
stress [2], are involved in chromosome deletions in early
stages of preneoplasia [3-5] before oncogene activation. These
deletions, seen in developing cancers as the most frequent
genetic alterations, have been considered passenger events
rather than drivers [6] of clonal expansion. The human Fhit
protein is encoded by the FHIT/FRA3B locus [7], the most
active fragile locus in human lymphoblasts, though not the
most fragile region in cells derived from other tissues [8]. Fhit
expression is lost or reduced in many precancerous lesions
and in >50% of cancers of humans [9]. Furthermore, Fhit
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knockout (Fhit-/-) mice are highly susceptible to carcinogen-
induction of tumors and FHIT replacement in these tumors, by
gene therapy, induced apoptosis and significantly reduced
tumor burden [10-12]. Numerous reports have confirmed that
the FHIT gene is a preferential target of allelic deletion and that
Fhit inactivation has roles in initiation, development and
progression of cancers ([13] for review), and we have recently
reported that Fhit protein deficiency causes reduced
expression of thymidine kinase, subsequent dTTP imbalance,
impaired DNA replication fork progression, and spontaneous
DNA breaks that are transmitted to daughter cells, leading to
genome instability [14]. Genomic instability is observed in
human precancerous lesions, and concurrent loss of Fhit
expression has been detected in precancerous lesions,
suggesting that, due to fragile site susceptibility to replication
fork stress, Fhit loss is among the earliest changes to occur in
the preneoplastic process [4,5]. We have concluded that loss of
Fhit, a genome ‘caretaker’, initiates the onset of genomic
instability in precancerous lesions that drives tumorigenesis
and links common fragile site instability to genomic instability
and cancer development. Following our finding that loss of Fhit
expression leads to accumulation of DNA damage in cells
established from Fhit-/- tissues [14], the goal of the current
research was to illustrate the consequences of loss of Fhit
caretaker function by demonstrating the ‘mutator’ phenotype of
Fhit-deficient cells and tissues.
Materials and Methods
Ethics Statement
The experiments involving isolation of mouse tissues for
DNA analysis and for establishment of cell lines was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocols for these experiments were
approved by The Ohio State University Institutional Animal
Care and Use Committee (IACUC, Protocol Numbers:
2007A0174-R2 and 2008A0151-R1).  All efforts were made to
minimize suffering as outlined in the protocols and approved by
the IACUC.
Cell lines, mouse tissues and reagents
We previously established mouse embryo fibroblast (MEF)-
derived cell lines from 3 Fhit+/+ and 3 Fhit-/- embryos for each
genotype, showed that -/- cell lines became immortalized at
early tissue culture passage and exhibited Copy Number
Variations (CNVs) [14]. Since most human cancers derive from
epithelial cells of major organs, we have also established
epithelial cell lines from +/+ and -/- baby mouse kidney tissue,
cloned lines from these cultures, compared proliferation
characteristics and examined the effect of carcinogen
treatment on +/+ and -/- cells. To define consequences of the
Fhit loss-induced genome instability in vitro, we have examined
CNVs and mRNA expression in these mouse cell models. To
examine in vivo effects of genome instability in -/- mouse
tissue, we have treated +/+ and -/- mice with 7,12-
Dimethylbenz[a]anthracene (DMBA, Sigma Aldrich), a
carcinogen known to induce mutations in mouse liver [15], and
have compared genome-wide exome sequences of +/+ and -/-
liver DNAs at 1 and 4 weeks post DMBA injection.
Fhit+/+ and Fhit-/- mouse kidney cells from C57Bl/B6
background mice were cultured in MEM with 10% FBS and 100
μg/ml gentamicin. At passage (P)15, cells were plated at a low
density (100 cells per 100 mm culture dish). After 10-12 days, 8
randomly chosen colonies were isolated and designated +/+
clones 1-8 and -/- clones 1-8. Fhit-/- cells that survived
carcinogen treatment were established after exposure of +/+
and -/- mouse kidney cells to DMBA at P20; 1 x 105 cells from
growing cultures were seeded in 60 mm dishes in medium
including 20 µM DMBA; 3 days after seeding, the medium was
replaced with normal medium and cells were cultivated. Two
weeks later, no colonies were observed in +/+ mouse kidney
dishes, whereas 13 colonies were observed among -/- mouse
kidney dishes. The colonies were reseeded and cells expanded
for further analyses (-/- DMBA-surviving cells).
Western blot analysis
Cells were lysed with RIPA buffer (Thermo Scientific)
supplemented with Halt Protease Cocktail Inhibitors (Thermo
Scientific). Proteins were separated by SDS gel
electrophoresis, transferred to nylon membranes and
immunoblotted with antisera against murine p21 (F-5) (Santa
Cruz), p53 (1C12), Survivin (71G4B7), MCL-1 (D35A5),
Cleaved-Caspase 3 (Asp 175), Caspase 3, PARP (Cell
Signaling), Fhit [11,14] and GAPDH (Calbiochem).
Copy number variation analysis
Genomic DNA was isolated from +/+ and -/- mouse kidney
cells at P4, +/+ and -/- cloned cells (n=3 lines), and +/+ and -/-
MEFs at tissue culture P3 and P25 (n = 3 lines) using DNeasy
Blood and Tissue isolation kit (Qiagen). Genomic DNA was
also isolated from +/+ and -/- B6 weanling tail tissue. Genomic
DNA samples were analyzed for CNVs at Jackson Labs using
the Affymetrix Mouse Diversity Genotype Array. The B6 +/+ tail
DNA served as reference DNA. This array simultaneously
assays 623,124 single nucleotide polymorphisms of 12 inbred
mouse strains and more than 900,000 invariant genomic
regions in the mouse genome [16]. After analysis of the
insertion/deletion data was completed, the single nucleotide
polymorphism (SNP) data was used to confirm that deletions
and gains were indeed due to B6 allele losses and gains rather
than to known germline deletions or to retention of 129svJ
alleles. In the results section, CNV loci are classified ‘Loci not
known to be fragile’ or ‘Loci known to be fragile’ referring to the
reports of Djalali et al [17] and Hosseini et al [18].
Colony formation assay
For colony formation assays, cells were plated at varying
densities into 100 mm culture dishes, grown for 14-21 days.
Cells were then fixed and stained with crystal violet and colony
numbers counted. For clonogenicity assays, cells were treated
with 5 or 20 µM DMBA 24 hr before plating. After DMBA
exposure, cells were washed with PBS and growth medium; 3
days later, the surviving cells were replated (2 x 105 cells per
100 mm dish) in growth medium and cultured for 3 wks. Cells
were then fixed, stained and colonies counted; mutation
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frequencies were calculated as average colony formation
efficiency.
Statistical Analyses
Results of clonogenicity experiments were expressed as
average values of three or four measurements. Error bars for
all experiments represent one standard deviation around the
mean. P values were determined by Student’s two-sided t test
in comparisons of results from experiments on Fhit positive and
negative cells.
ß-galactosidase staining for detection of senescent
cells
Senescent cells were detected by ß-Galactosidase staining
[19] using the Senescence ß-Galactosidase Staining Kit (Cell
Signaling) and recommended protocol. Stained cells were
observed and enumerated by light and phase-contrast
microscopy.
Gene expression analysis
Total RNA was isolated from +/+ and -/- mouse kidney cells
at P4 and P15 (n=1 for the kidney cultures) and +/+ and -/-
MEFs at P3 and P27 (n=3 for the MEF cultures [14]) using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. cDNA was synthesized using RT2 First Strand kit
(Qiagen) and gene expression was examined by RT² Profiler
PCR Array (Mouse Cellular Senescence PCR Array) according
to the user manual instructions. Data was analyzed by Web-
Based PCR Array Data Analysis (Qiagen). Genes differentially
regulated in Fhit-/- cells vs Fhit+/+ cells were reported as relative
fold-changes. Relative fold-changes, 2^(-ΔΔCt), were
calculated by dividing the normalized gene expression, 2^-ΔCt,
in the test sample by the normalized gene expression, 2^-ΔCt,
in the control sample. Specifically for the samples tested,
relative fold-changes in the genes were calculated by
comparing 2-ΔCt values in +/+ mouse kidney cells at P4
compared to +/+ and -/- mouse kidney cells at P15. Fold-
changes were also reported for MEFs, comparing 2-ΔCt values
for +/+ tissue culture at P3 with and -/- MEFs at tissue culture
at P27.
Trp53 RT-PCR and Sequencing
Total RNA was extracted and cDNA synthesis was
performed for 15 min at 42°C using 1 µg of total RNA as
template, RT primer and quantitect reverse transcriptase
(Qiagen Quantitect Reverse Transcription Kit, USA). PCR was
then performed using Trp53 gene specific primers: forward 5’
TGCTCACCCTGGCTAAAGTTCTGT 3’ and reverse 5’
ATGCAGACAGGCTTTGCAGAATGG 3’. Per reaction, 1 U of
Platinum PCR SuperMix High Fidelity Taq polymerase was
used and the cycling conditions were: pre-incubation for 5 min
at 95°C, 30 cycles of 15 s at 95°C, 30 s at 54°C and 2 min at
68°C and final incubation at 4°C. PCR product quality was
analyzed on a 0.8% agarose gel and purified for sequencing
analysis via Qiagen QIAquick PCR Purification Kit. Sequencing
samples containing 6.4 pmol of primer and 45 ng of template
DNA were brought to a total of 12 µl with DNAse free water and
sent for sequencing to the OSUCCC Nucleic Acid Shared
Resource. Sequencing primers for the Trp53 gene were:
forward 5’ TGCTCACCCTGGCTAAAGTTCTGT 3’; reverse 5’
ATGCAGACAGGCTTTGCAGAATGG 3’; a second forward 5’
TTACCAGGGCAACTATGGCTTCCA 3’; second reverse 5’
TTCGAGATGTTCCGGGAGCTGAAT3’.
Transfection
The mammalian expression vectors, pRcCMV-FHIT,
pRcCMV-empty vector, pRcCMV-WT TP53 or pRcCMV-mouse
Trp53 A135P, were transfected into mouse kidney cells using
Lipofectamine 2000 (Invitrogen) reagent. Mouse kidney cells
were plated on 60 mm2 dishes and cultured to 60-80%
confluence. Transfections were carried out with 1 µg plasmid
DNA and 2 µl Lipofectamine diluted in Opti-MEM (Gibco) and
incubated for 30 min at room temperature. Cells were washed
in Opti-MEM, overlaid with the plasmid DNA/Lipofectamine
solution and incubated overnight at 37° C. To optimize FHIT
plasmid transfections, 1 µg DNA was mixed with either 2 or 4 µl
Lipofectamine. Cell lysates were collected 24 h post-
transfection for western blot analysis.
Exome sequencing of genomic DNAs of mouse liver
tissue and mouse kidney cell lines
Genome DNA from kidney cells or liver tissue of the following
genotypes was prepared for exome sequencing: wild-type (Fhit
+/+) C57BL/6 (B6) and Fhit−/− on B6 background. B6 mice were
purchased from the Jackson Laboratory (Bar Harbor, ME). Fhit
−/− mice were generated as described [10,11]. Mice were
treated at 10-14 days of age with a single intraperitoneal
injection of corn oil (1 mouse of each strain, mock), or with a
single intraperitoneal injection of corn oil containing 20 nmol/g
body weight DMBA (2 mice of each strain). Mice were
sacrificed 1 or 4 wks after treatment. Liver, lung and spleen
were removed from each mouse and stored in All Protect
Tissue Reagent (Qiagen). The mouse kidney cell lines (+/+
P22, -/- P22, -/- cl 6 P20, -/- DMBA-surviving culture P22) were
treated with DMBA as described above. Total genomic DNAs
were isolated using DNeasy Blood and Tissue (Qiagen) and
total protein was prepared by RIPA buffer lysis. Genomic DNA
samples were analyzed for exome sequences at EdgeBio
using Illumina HiSeq 2000, using the Agilent SureSelect Mouse





5990-7235en_lo.pdf. The kit results in a ~50 Mb capture region
covering ~221,784 exons and 24,306 genes. C57BL/6 (B6)
DNA served as reference genome sequence.
Exome sequence data analysis
The small insertions and deletions (indels) identified from
exome sequencing data using the GATK package were further
filtered to remove any indel with low mapping quality (MQ<10),
indel calling score (QUAL<10) or reads depth (DP<10). For all
the exome data analysis, only indels passing the above filtering
step were used. The indel frequency was calculated using the
Fhit-Deficiency Promotes Clonal Expansion
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number of reads containing indels (reads mapped to alternative
allele 1 and 2) divided by the total number of reads mapped to
a specific indel location. Matlab “hist” function was used to
generate histograms of indel frequency. To plot the frequency
histogram, moving average of the frequency counts by Matlab
“smooth” function was used to generate more smooth lines. To
determine and remove common indels shared by two samples,
the exact indel locations were used to cross-check between
two indel summary files. To retrieve genes with indels in the
coding region, RefSeq transcripts of mouse genome mm9 was
used.
SNP sequences for each kidney and liver exome data set
was analyzed to determine the number of genes containing
clustered mutations. A gene containing a minimum of three
single nucleotide variations was defined as a gene containing
clustered mutations. The total number of genes containing
clustered mutations was determined following the elimination of
all genes that did not exhibit clustered exome mutations.
Results
Allele copy number alterations in Fhit-/--derived cell
lines and tissue
For examination of the genome instability induced by loss of
Fhit expression, we assessed somatic CNVs, defined as DNA
gains or losses spanning >10 kb, using genomic DNA isolated
from +/+ and -/- mouse kidney cells (at P4) and cloned cells
established from mouse kidney cells (n=3), with wild type (WT)
+/+ C57BL/6 (B6) tail DNA as reference. We have included the
CNV results reported previously for MEF cells at P3 and P25
(n=3) and -/- tail DNA [14] for comparison. Figure 1A, B
summarizes CNVs of >10 kb detected across the cell types
tested; the genomic changes in Figure 1A represent alterations
observed at genomic sites not currently known to be fragile and
Figure 1B summarizes alterations observed at chromosome
fragile sites, based on the reports by Djalali et al [17] for mouse
fibroblasts and Hosseini et al [18] for epithelial cells. Blue in
columns indicate loss of alleles, and red gain of alleles. The
mean fold-change of lost alleles ranged from 0.26 to 0.83 and
of gained alleles from 1.51 to 2.77 (see Table S1 for details of
individual CNVs). As reported [14] previously, CNVs, mostly
allele losses, occurred more frequently in -/- MEFs than in the
comparable +/+ cells. CNVs were also detected in the genome
of -/- weanling tail tissue, illustrating the existence of genome
instability in normal tissue not related to pre-cancerous lesions
and suggesting that weanling tail tissue developed from few
clones. The alleles involved in most CNVs are unique to mouse
kidney or MEF-derived cells. Interestingly, the established
kidney cell lines and subcloned lines of both +/+ and -/-
genotypes exhibit few CNVs in comparison to the -/- MEF cell
lines. Most CNV loci in the tail tissue differ from those detected
in the cell lines and do not correspond to known CNVs in the
different mouse strains. This result suggests that specific CNVs
may be selected under in vitro conditions and that different
genome alterations contributed to survival of individual cell
lines.
The mouse kidney cell model: establishment and
comparison to the MEF model
MEF cell lines were previously established from three +/+
and three -/- embryos and examined at early and late tissue
subcultures, before and after senescence and immortalization
[14]. As previously reported, CNVs were not observed in +/+
MEF cell lines while several were detected in all -/- MEF cell
lines (shown in Figure 1 for comparison with the CNV analysis
of the kidney cell lines and clones). As noted previously, two of
three post-senescence -/- MEF cell lines acquired
amplifications within chromosome band 10D2 encompassing
the murine Mdm2 gene (Figure 1B), an oncogene frequently
involved in cell transformation [20], and Mdm2 gene
amplification correlated with ~4-fold increase in Mdm2 mRNA
expression (see below for expression data).
Mouse kidney cells from P4 and each of eight cell lines
subcloned from them at P17 were observed during
establishment and proliferation at progressive tissue culture
passages; Figure 2A illustrates changes in expression of
survival–associated proteins from P4 to P22 of the +/+ and -/-
kidney cells. The +/+ kidney cells lose expression of Fhit
gradually with passage, show increasing Survivin expression
and steady Mcl1 to P22 [21,22], two modulators of apoptosis.
This alteration of Fhit expression levels in +/+ cells may be due
to epigenetic modifications, since we have not detected allelic
losses at the fragile Fra14a2 locus within the murine Fhit gene
(Figure 1B). The most striking changes occurred in the -/-
kidney cells: the p53 level increased dramatically between P7
and P12 and the Cdkn1a gene product, p21 [23], an important
downstream p53 target, disappeared abruptly in parallel,
strongly suggesting that a mutant Trp53 gene and mutant p53
protein appeared post P7 and -/- cells carrying this mutation
expanded to take over the culture by P12; though Survivin may
increase slightly in parallel, Mcl1, an anti-apoptotic protein,
increased in expression abruptly at P15 through P22. The
absence of p21 expression is due to mutation in the p53
protein in Fhit -/- cells; when tested at P24 these cells, unlike
the +/+ cells at early and late passage and -/- cells at early
passage, displayed a single missense mutation, a G to C
substitution, changing the amino acid at position 135 from
alanine to proline; this mutation is in the DNA-binding domain
of p53 and likely affects its ability to transactivate the Cdkn1a
gene. Late passage -/- kidney cells expressing the mutant p53
protein were transfected with a WT p53 expression vector and
p21 was re-expressed in the transfected cells (Figure 3).
Similar over-expression of FHIT in the same -/- kidney cells did
not result in re-expression of p21 protein (Figure 3) though it
has been reported that Fhit overexpression induces expression
of Cdkn1a mRNA [24] in H460 lung cancer cells that are
negative for endogenous Fhit protein expression. This
difference in results may be due to differences in cell lines
used. Perhaps there is an accessory protein involved in the
transcriptional activation, a protein that is missing or altered in
the -/- kidney cells. Since Fhit is a cytoplasmic protein that is
unlikely to act as a transcriptional activator, it is likely that its
activation of Cdkn1a mRNA is indirect, and involves nuclear
activating proteins.
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Figure 1.  CNVs in MEFs, mouse kidney-derived cells and mouse tissue.  (A) Summary of CNVs detected at chromosome loci
not known to be fragile, in mouse kidney-derived cells, kidney-derived cloned cells, and pre- and post-senescence MEF cell lines
derived from +/+ and -/- mice, and -/- tail tissue, using the Affymetrix Mouse Diversity Genotype Array; CNV data for MEF cultures
was previously reported [14] and is included here for comparison to the kidney culture DNAs. Blue columns indicate allele loss (fold-
change range, 0.26 to 0.61), and red columns indicate gain (fold-change range, 1.51 to 1.91). For more detail, see Table S1. (B)
CNVs at chromosome fragile loci. CNVs at fragile loci detected in the same mouse cell lines and tissues. Blue columns indicate
allele loss (fold-change range, -0.5 to -0.83) and red columns indicate gain at specific fragile chromosome loci (fold-change range,
1.50 to 2.51).
doi: 10.1371/journal.pone.0080730.g001
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During cultivation, we observed morphological heterogeneity
in the Fhit-/- kidney-derived cells and isolated clonal cell
populations to further examine heterogeneity in these cells; 8
cloned cell lines were established from +/+ and -/- cells, stained
with crystal biored and observed by microscopy (Figure 2B and
Figure S1). The Fhit-/- clones appeared more morphologically
varied than Fhit+/+ clones (Figure 2B, Figure S1), though there
were only a few variations in CNVs. CNVs were not observed
in Fhit+/+ mouse kidney cells at P4, though there were some
allelic gains in one of the +/+ clones (Figure 1).
Figure 2.  Mouse kidney cells exhibit progressive changes during in vitro culture.  (A) Immunoblots for p53, p21, Survivin,
Mcl1, Fhit and GAPDH expression in the mouse kidney cells with progressive culture. In +/+ cells, Fhit expression is decreased
gradually with passage progression, but capacity for apoptosis is likely maintained at late passage as shown by expression of p21.
-/- cells undergo loss of apoptotic response with passage progression, dramatic increase of p53 in parallel with abrupt loss of p21
expression and dramatic increase of Mcl1 expression. (B) Representative micrographs of fixed, crystal biored stained +/+ and -/-
kidney cell clones exhibiting morphological diversity, particularly in the -/- clones (see also Figure S1).
doi: 10.1371/journal.pone.0080730.g002
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Increased clonogenicity and resistance to DMBA in late
passage Fhit-deficient cells
Because -/- kidney cells accumulate genome alterations due
to loss of the Fhit caretaker function and showed striking
changes in expression of the p53-p21 cell cycle control
pathway, we were interested in how response to carcinogen
exposure might differ in +/+ and -/- epithelial cells. To
determine the effect of loss of Fhit expression on sequential
precancerous changes in vitro, we assessed clonogenicity in
each passage of the MEF and kidney cell lines. -/- kidney cells
showed limited clonogenicity relative to +/+ kidney cells at P5
to P12 (50 to 159 colonies/500 cells for Fhit+/+ cells vs 8 to 26
colonies/500 cells for Fhit-/- cells) (Figure 4A and Figure S2A).
After P15, Fhit-/- kidney cells exhibited greater clonogenicity
than Fhit+/+ cells (113 to 128 colonies/500 cells for Fhit+/+ cells
vs 170 to 223 colonies/500 cells for Fhit-/- cells). Similar results
were observed in post-senescence MEF cells (0 to 0.25
colonies/500 cells for +/+MEF cells vs 30 to 50 colonies/500
cells for -/- MEF cells) (Figure 5A).
Next, we examined clonogenicity of early (P10) and late
(P21) passage kidney cells treated with DMBA, an inducer of
mutations and tumor initiator [15,25]. The Fhit+/+ and Fhit-/-
kidney cells were treated with 20 µM DMBA for 24 h and plated
in 10 cm dishes. Almost no colonies were observed in Fhit+/+
and Fhit-/- cells at P10 and Fhit+/+ cells at P21 after DMBA
treatment, while Fhit-/- cells at P21 formed 76 colonies/2000
cells (Figure 4B). Similar results were obtained in post-
senescence MEF cells (0 colonies/2000 cells for MEF+/+3 cells
vs 20 colonies/2000 cells for MEF-/-5 cells) (Figure 5B).
Microscopic observation of cells 3 days after DMBA treatment
showed decreased surviving cells and morphological changes
in +/+ and -/- kidney cells at P10, +/+ kidney cell at P21 (Figure
S2B, C) and in MEF+/+3 cells (Figure S3), likely due to
elimination of cells by apoptosis, as suggested by ß-
galactosidase staining of some cells; -/- kidney cells at P21 and
MEF-/-5 cells showed less morphologic change and ß-
galactosidase expression [19], a marker of senescence. The
results imply that the clonogenic late passage Fhit-deficient
cells had acquired increased resistance to DMBA-induced
apoptosis and cell cycle arrest.
To examine differences in expression of apoptosis related
proteins, immunoblots were performed using cells before, and
6 and 24 h after exposure to 20 µM DMBA. The expression of
cleaved-Caspase 3 and cleaved PARP were detected after
DMBA treatment, indicating that DMBA induced apoptosis in
kidney (Figure 4C) and MEF cells (Figure 5C). Apoptosis-
associated proteins were similarly expressed in -/- kidney cells
at P22 (Figure 4C) and MEF-/-5 cells (Figure 5C). Although the
-/- P22 kidney cells had shown few DMBA-induced
morphological changes (Figure S2C), copious cleaved-
Caspase 3 was detected in the -/- P22 cells (Figure 4C). For
investigation of cells that developed resistance to DMBA, we
established DMBA-surviving -/- kidney cells from colonies that
formed 2 wks after DMBA treatment. After expansion of these
colonies, and treatment with 20 µM DMBA for 24 h,
morphology and protein expression were again examined. The
-/- kidney cell DMBA survivors showed neither apoptosis nor
morphological changes after DMBA treatment (Figure S4).
Next we examined expression of apoptosis-related protein
expression after DMBA treatment. Neither the increase in
expression of cleaved-Caspase 3 nor cleaved-PARP was
detected in DMBA surviving -/- kidney cells on further DMBA
treatment (Figure 4C, right panel), in agreement with absence
of ß-gal staining of the cells.
Mechanisms of DMBA resistance differ in mouse
kidney and MEF cells
We also assessed expression of apoptosis-related proteins
Mcl1, Survivin and p21 in the DMBA-treated kidney cells
(Figure 4C). Mcl1 is an anti-apoptotic protein that confers
resistance to Caspase-3 mediated apoptosis [22]. The level of
expression of Mcl1 in Fhit+/+ kidney cells at P22 and P10 was
Figure 3.  Restoration of p21 expression in late passage Fhit-/- cells by WT p53 overexpression.  (A) Western blot analysis of
p53, p21 and vinculin in Fhit -/- mouse kidney cells transfected with either control vector (EV), WT or A135P mutant Trp53
expression vector. The end lane shows expression of p21 in early passage Fhit -/- kidney cells treated with DMBA for 24 h. (B)
Western blot analysis of p21, Fhit and GAPDH in Fhit-/- mouse kidney cells, at tissue culture passages shown across tops of gels,
transfected with control (EV) or WT FHIT expression vector. The end lane contains lysate from early passage Fhit-/- mouse kidney
cell treated 24 h with DMBA for a p21 positive control.
doi: 10.1371/journal.pone.0080730.g003
Fhit-Deficiency Promotes Clonal Expansion
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e80730
Figure 4.  Expression of apoptosis-related proteins in -/- kidney cells with and without exposure to DMBA.  (A) Clonogenicity
of +/+ and -/- kidney-derived cells with passage progression. Note the remarkable increase in colony number in -/- cells post P12
while the colony number for +/+ cells shows a steady rise to P12 and then decreases. *P <0.05; **P =0.069. (B) Clonogenicity of +/+
and -/- kidney cells after a 24 h DMBA (20 µM) treatment (at P10 and P21). *P <0.05. (C) Expression of apoptosis-associated
proteins in the kidney cells before and 6 and 24 h after DMBA exposure, detected by immunoblot (at P10 and P22) (left panel).
Expression of apoptosis-related proteins in -/- DMBA survivors (right panel): Note that cleaved Caspase 3 and cleaved PARP, both
apoptosis markers, are markedly decreased in the DMBA-surviving cells whereas they were very similarly activated in the +/+ and
-/- cells following initial DMBA exposure. In (A, B) bar graphs represent means and error bars standard deviations from at least 3
independent experiments.
doi: 10.1371/journal.pone.0080730.g004
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similar, while in Fhit-/- kidney cells at P22 Mcl1 expression was
increased vs P10 cells. These expression levels were
decreased in response to DMBA treatment in both +/+ and -/-
kidney cells. Mcl1 expression levels were similar in MEF+/+3
and MEF-/-5 cells before DMBA treatment, and is still
expressed in MEF-/-5 cells 24 h after DMBA treatment unlike
MEF+/+3 cells (Figure 5D). The change in Survivin expression
level in MEF cells after DMBA treatment was also interesting,
because MEF +/+3 cells showed decreased Survivin
expression, while MEF -/-5 cells showed an increase (Figure
5D). Markedly decreased expression of p21 was seen in -/-
kidney cells at P22 without treatment. This expression was up-
regulated after DMBA treatment in +/+ kidney cells at P10 and
P22 and -/- kidney cells at P10, whereas -/- kidney cells at P22
exhibited negligible expression of p21 after DMBA treatment
(Figure 4C). In MEF cells, induction of p21 is observed in both
MEF+/+3 and MEF-/-5 cells after DMBA treatment (Figure 5D).
Thus, although -/- kidney cells and MEF cells resistant to
DMBA treatment were selected, the resistance mechanisms
differed. The DMBA-surviving -/- kidney cells showed highly
down-regulated cleaved Caspase 3 and reduced cleaved
PARP in the complete absence of p21 expression due to
mutated p53; the MEF-/- DMBA survivors instead expressed
WT p53 and highly activated p21 but expressed a steady level
of Mcl1 and many-fold increased Survivin during DMBA
treatment. Thus, the kidney -/- cells became DMBA resistant
through silencing apoptotic signals and the MEF-/- cells
became resistant through activation of anti-apoptotic signals.
Figure 5.  Decreased sensitivity to apoptosis-related proteins in late passage -/- MEF cells.  (A) Clonogenicity of +/+ and -/-
MEFs at P30. The asterisks represent significant differences (*P <0.05) between +/+ and -/- MEFs. (B) Clonogenicity of MEF+/+ 3
and MEF-/- 5 cells after treatment with 20 µM DMBA for 24 h (P31). Bar graphs represent the means, and error bars the standard
deviation from at least 3 independent experiments; (*P <0.05). (C, D) Western blots for Caspase 3, PARP, Survivin, Mcl1, p53, p21
and GAPDH expression in MEF+/+ 3 and -/- 5 cells before and 6 and 24 h after 20 µM DMBA treatment at P31. Note that although
the +/+ and -/- MEFs show similar expression patterns for cleaved Caspase 3 and cleaved PARP after DMBA treatment, the
MEF-/-5 cells likely survive DMBA treatment as shown in (B) because Survivin and Mcl1 are up-regulated in these cells by 24 h
DMBA treatment, in contrast to the loss of these proteins at 24 h after DMBA in the MEF+/+3 cells.
doi: 10.1371/journal.pone.0080730.g005
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mRNA expression profile changes in Fhit+/+ and Fhit-/-
cells
To examine gene expression changes in early and late
passage kidney and MEF-derived cells, total RNA was isolated
from +/+ and -/- mouse kidney cells at P4 and P15 and +/+ and
-/- MEFs at P3 and P27 and cDNA synthesized. Senescence-
associated gene expression was assessed using the RT²
Profiler PCR Array (Mouse Cellular Senescence PCR Array).
Data was analyzed using the Web-Based PCR Array Data
Analysis program (Qiagen). Figure 6 summarizes the results
for those mRNAs that showed altered expression in the kidney
cells where shades of blue illustrate varying levels of reduced
mRNA and shades of red varying levels of increased mRNA
(complete results for the expression studies are shown in Table
S2 and S3). Among down-regulated genes, Cd44, Cdkn1a
(p21) are each down more than 10-fold in -/- kidney cells, a
greater change than seen in the +/+ kidney cells; Twist1 is also
down 10-fold in -/- kidney cells vs 2-fold down in +/+ kidney
cells. Creg1 is down 5-fold and it has been observed that
Creg1 is decreased during immortalization [26]. Nox4 [27,28]
and Egr1 [29] are down 10-fold and Fn 1 5-fold. On the other
hand, Cdkn1c, Tert, Ets2, Ing1, Nfkb1, Sod1, E2f1 [30],
Cdkn2d and Ccnd1 are up ~2-fold in -/- kidney cells and
Chek2, Cdkn2c, Rbl1 [31,32] and Chek1 are up ~5-fold and
Cdk6 up 10-fold in -/- kidney cells. In Figure 6, first column,
gene names marked in bold indicate possibly interconnected
signal pathways that are altered in -/- kidney cells as the basis
for the enhanced proliferation, reduced apoptosis/senescence,
increased clonogenicity and DMBA resistance observed. Note
that Trp53 is bold in Figure 6, to reflect the large increase in
p53 protein observed in the -/- kidney cells.
Figure 7 illustrates the varying expression patterns among
both the +/+ and -/- MEF cultures. Note the increased
expression of Mdm2 in two of the -/- MEF lines, along with
increased expression of Atm, E2F1 and Bmi1 in two MEF lines.
We did not detect common mRNA expression changes in
kidney and MEF cells at late vs early passage cells in accord
with the finding that MEF and kidney cells in vitro selected
different signal pathways for survival in culture. Exceptions are
increases in expression of E2f1 and Ccnd1 in -/- cells of both
cell types, perhaps illustrating the centrality of these proteins in
control of cellular proliferation.
DMBA-induced mutations are increased in Fhit-/- liver
tissue and kidney cells
To examine the effect of Fhit-deficiency on in vivo
carcinogen-induced mutations, the exomes of +/+ and -/-
mouse liver tissues (see Figure 8A for expression of Fhit in the
tissues) were sequenced 1 wk and 4 wks following DMBA
treatment; exomes of untreated +/+ and -/- liver tissues were
also sequenced. The total number of reads for each sample
ranged from 77,650,121 to 91,060,272, and at least 98.6% of
reads were aligned. The mean coverage ranged from 82X to
98X, and at least 98.1% of base pairs were covered at least
10X. After the initial filtering for small insertions and deletions
(indels) based on quality scores and depth of reads (see
Materials and Methods), we then subtracted all indels that were
identical in both the untreated +/+ and untreated -/- samples for
all downstream analyses. There was a 4-fold increase in the
number of indels in the -/- untreated liver tissues compared to
the +/+ untreated, and a 3-fold increase in the number of indels
in the DMBA-treated -/- liver tissues compared to matching +/+
liver tissues (Figure 8D). Many of the indels in the +/+ and
more in the -/- samples were present at an allele frequency of
greater than 0.9. Because the previous CNV analysis [14]
revealed the presence of germline variants in the -/- line, we
presume that the indels present at an allele frequency
approaching 0.5 or 1.0 may be germline variants. Thus, to
focus on somatic mutations caused by DMBA treatment or a
combination of Fhit absence and DMBA exposure, only indels
present in fewer than 50% of sequencing reads were
considered somatic (Figure 8B and C). Furthermore, we
excluded indels that were identical between untreated and
DMBA-treated samples. In the untreated groups, the -/- tissues
had 1.5-fold increase in the number of somatic indels
compared to the +/+ tissues, whereas there was no significant
difference in the number of somatic indels in the DMBA-treated
+/+ vs -/- samples (Figure 8D). Our analysis may be an
underestimate of the fold-increase in the number of somatic
indels present in the -/- DNA compared to the +/+ DNA, as the
majority of indels in the -/- tissues were present at an allele
frequency >0.3, while the majority of indels in the +/+ tissues
were present at an allele frequency <0.3. Nevertheless, the
1.5-fold increase in somatic indels in the untreated -/-
confirmed in vivo the occurrence of mild genome instability in
Fhit-negative cells.
We next considered possible progressive changes 1 wk and
4 wks following DMBA treatment. In the +/+ tissues, there was
an increase in the number of somatic indels (allele freq < 0.3),
but no other major changes. In the -/- tissues, there was an
initial decrease in the number of somatic indels with allele
frequency <0.3 one week after DMBA treatment. However, at
both 1 and 4 wks post-DMBA treatment, there was an increase
in the number of indels with an allele frequency ranging
between 0.3 and 0.6 (Figure 8B). This increase in frequency
may indicate selective expansion of some liver cell populations
with DMBA-induced beneficial mutations. We have also
obtained exome sequences for DNA of +/+ and -/- kidney cell
lines at late passage, with and without DMBA exposure, and a
figure illustrating indel frequencies in the -/- cells is shown in
the histogram in Figure 9A and a summary Table in Figure 9B.
A striking feature of the data in Figure 9B is that each of the -/-
cell lines has accumulated ~3-fold more indels than the +/+
cells, though all were cultured for the same number of
passages.
We have analyzed the exome sequencing data in several
ways, by examining overlap of detected mutations,
identification of indels unique to each individual DNA sample as
in Figure 8B, and for the -/- control liver DNA vs the 1 wk and 4
wk DMBA treated liver DNAs (Figure 8C). Many of the
candidate mutations involve expanded or contracted
minisatellite sequences and many involve deletions or
insertions of a few nucleotides. See Table S4 for lists of indels
in the +/+ and -/- liver DNAs with and without DMBA treatment,
after removal of common indels and Table S5 for the list of
indels in the mouse kidney cells that survived DMBA treatment.
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Figure 6.  Gene expression changes in +/+ and -/- kidney cells at late vs early passage.  mRNA expression in kidney cells at
early and late passages was examined by RT² Profiler PCR Array (Mouse Cellular Senescence PCR Array, Qiagen) and fold
change was calculated. Dark blue in the columns indicates >10-fold decrease of gene expression at late passage, medium blue
indicates >5-fold decrease and light blue indicates >2-fold decrease. White columns indicate less than 2-fold change. Light pink
indicates >2-fold increase of gene expression at late passage, medium pink indicates >5-fold increase and red indicates >10-fold
increase in expression. Gene names are given in blue or red for those genes that show significant differences in expression. Gene
names marked in bold indicate possibly interconnected signal pathways that are altered in -/- kidney cells.
doi: 10.1371/journal.pone.0080730.g006
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Figure 7.  Gene expression changes in MEF cells.  mRNA expression in MEF cells at early and late passages was also
examined using the RT² Profiler PCR Array and fold change was calculated. Dark blue in the columns indicates >10-fold decrease
of gene expression at late relative to early passage, medium blue indicates >5-fold decrease and light blue indicates >2-fold
decrease. White columns indicate less than 2-fold change. Light pink indicates >2-fold increase of gene expression at late passage,
medium pink indicates >5-fold increase and red indicates >10-fold increase in expression. Gene names are given in blue or red for
those genes that show statistically significant differences in expression in the -/- vs +/+ cells in at least two of the three -/- vs +/+
MEF cell lines. Note the intra- and inter-strain variation in expression changes among the three +/+ and -/- MEF cell lines and the
few changes in common with the kidney cell lines (E2f1, up in -/- of both cell types, Ccnd1 up in two of three -/-MEFs as well as -/-
kidney); also Atm and Chek2 up in -/- lines, perhaps indicating ongoing DNA damage.
doi: 10.1371/journal.pone.0080730.g007
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Figure 8.  Exome insertions/deletions in mouse livers after DMBA exposure.  (A) Immunoblot detection of Fhit and GAPDH
expression in livers of +/+ and -/- mice after DMBA treatment. (B) Histogram of spectrum of substitutions in the exomes of +/+
mouse and -/- mouse liver treated with or without DMBA at indel frequencies <0.3. (C) Frequency histogram of unique indels of each
-/- DNA sample. (D) Summary of insertions/deletions in the livers of control and DMBA treated mice at 1 and 4 wks post exposure.
The final column represents numbers of unique indels that occurred at low frequency in liver DNAs of individual -/- and +/+ mice,
possibly due to the carcinogen treatment. Indels that were common to all the mice or common to the +/+ or -/- DNAs at these low
frequencies were subtracted. Note that the largest difference is between the control, untreated mice, with 201 indels in the -/- liver
vs 137 in the +/+ liver. The control livers were from B6 mice from Jackson laboratory while the -/- livers were from -/- mice
backcrossed ~9x to B6 (also Jackson lab derived many years ago) and maintained by brother-sister matings for several years. Thus
the B6 control DNA would exhibit many differences relative to the -/- background genes.
doi: 10.1371/journal.pone.0080730.g008
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Discussion
In hereditary cancers, genomic instability arises as a result of
germline mutations in DNA repair genes; this genome
instability drives cancer development in the familial cases, as
predicted by the mutator hypothesis. For sporadic cancers the
molecular basis of genomic instability is not known, but
sequencing of the genomes of many cancers have suggested
that mutations in known DNA repair genes are infrequent,
possibly ruling out the mutator hypothesis for these cancers.
According to a prevailing proposal, the mutation patterns
observed by cancer cell large scale sequencing, documenting
Figure 9.  Exome insertions/deletions in mouse kidney cells with and without DMBA exposure.  (A) Histogram of indel
frequencies (<0.5) in -/- kidney DNAs from exome sequence data after subtraction of indels common to all of the -/- cells, -/- kidney
cells at P22, -/- clone 6 kidney cells (cloned at P17 and grown for 3 more passages after cloning), and -/- kidney cells that survived
treatment with DMBA at P22; (B) Summary of insertions/deletions in the kidneys of +/+ control and -/- samples with and without
DMBA exposure. The final column represents numbers of unique indels that occurred at low frequency (f ≤ 0.5) in kidney DNAs of
individual +/+ and -/- mice. Indels that were common to all the mice or common to the +/+ or -/- DNAs were subtracted.
doi: 10.1371/journal.pone.0080730.g009
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TP53, ataxia telangiectasia mutated (ATM) and cyclin-
dependent kinase inhibitor 2A (CDKN2A; which encodes
p16INK4A and p14ARF) mutations, support the oncogene-
induced DNA replication stress model, which attributes
genomic instability and TP53 and ATM mutations to oncogene-
induced DNA damage [1]. According to this proposal, genome
instability in sporadic cancers results from the oncogene
induced collapse of DNA replication forks, which in turn leads
to DNA double strand breaks and genomic instability.
The mutator hypothesis predicts that in sporadic cancers,
too, mutations affecting caretaker genes should occur early in
cancer development and since targeted sequencing studies to
look for mutations in known DNA repair and mitotic checkpoint
genes failed to identify genes that were frequently mutated in
sporadic human cancers, the mutator hypothesis has fallen out
of favor. Our current results suggest that Fhit might fit the
prediction that ‘mutations affecting caretaker genes should
occur early in cancer development’; certainly deletion of Fhit
has been shown in many sequencing studies of multiple cancer
types. Figure 10 presents a model that summarizes the results
of this study showing that Fhit deficiency provides the ‘soil’ for
mutation and precancerous changes during cancer initiation, in
proliferative, senescence, apoptosis and survival pathways.
In vitro growth and genome instability in Fhit-/- vs Fhit+/+
cell lines
As the model in Figure 10 indicates, we propose that early
loss of the Fhit caretaker function sets the stage for
subsequent mutation accompanied by survival pressures for
expansion of clones with heterogeneous genomic, likely
epigenetic, and expression changes. It is interesting that the
MEF-/- cell lines show more frequent copy number alterations
Figure 10.  Fhit loss provides a cellular environment for selective clonal expansion.  Drawing of our model summarizing the
results of this study. Fhit-deficiency causes dNTP pool imbalance [14] and leads to genome instability and accumulation of
mutations, under selective pressures such as tissue culture conditions or carcinogen exposure. Thus, under selection for growth,
Fhit-deficient cells become impaired in the ability to eliminate cells through apoptosis and senescence. Although many cells are
eliminated, some survive due to precancerous changes. Thus, the genome instability induced by Fhit loss serves as the “soil” for
selective growth and progression of precancerous clones.
doi: 10.1371/journal.pone.0080730.g010
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than the kidney cell line and derived clones. This may be
deceptive since we studied only one kidney cell line from each
strain, though each MEF-/- cell line shows more CNVs than the
kidney -/- cell and its clones, with only a few CNVs that differ in
the clones relative to the parental cell line 1 of the kidney +/+
clones has gained CNVs and the other two have just a few
losses, similarly to the -/- kidney clones. This is in stark
contrast to the +/+ MEFs, early and late passage, with no
CNVs. These differences may be because the epithelial cells
are more likely to show smaller genomic alterations and
mutations and respond to survival pressures through genome
and chromatin methylation, a subject for future investigation. It
will be necessary to examine CNVs in more cell types from the
-/- mice, including embryonic stem cells and tissues of fetal and
neonatal organs as well as established cell lines to understand
the patterns of CNVs in primary tissues and established cells
after various environmental exposures and selective pressures.
Protein expression
Through protein and mRNA expression studies, we have
investigated the consequences of loss of the Fhit caretaker
function as summarized in the Figure 10 model. For the
immortalization and escape from senescence of the -/- kidney
cell culture, it seems likely that mutation of the Trp53 gene was
the initial event that led to up-regulation of anti-apoptotic
proteins and down-regulation of the executioners of apoptosis.
These and associated regulatory events led to increased
clonogenicity following tissue culture P12, though cleaved
caspase 3 and cleaved PARP were expressed at high levels
after exposure to DMBA in both the +/+ and -/- kidney cells.
Clearly DMBA exposure kills many of the two cell types. A
striking difference between the +/+ and -/- kidney cells was the
increased frequency at which the -/- kidney cells survived
DMBA exposure (Figure 4B) and were then resistant to further
killing by DMBA (Figure 4C right panel), suggesting that the -/-
kidney cells exhibit a higher mutation frequency following
DMBA exposure, a conclusion consistent with a ‘mutator’
phenotype. It will be important to establish additional epithelial
-/- cell lines to examine additional mechanisms of selection for
immortality and escape from apoptosis/senescence.
+/+ MEFs, in contrast to the +/+ kidney cells, showed very
poor clonogenicity at P30 with clonogenicity of untreated -/-
MEFs up to 50-fold higher and 20-fold higher after DMBA
treatment (Figure 5A,B), again consistent with a mutator
phenotype for the -/- MEFs.
mRNA Expression changes
The Mouse Cellular Senescence RT² Profiler™ PCR Array
(http://www.sabiosciences.com/rt_pcr_product/HTML/
PAMM-050A.html) profiles the expression of 84 key genes
involved in loss of ability of cells to divide. The cellular
senescence program leads to activation of p53 and pRb
signaling and to withdrawal from the cell cycle during very early
tissue culture passages. The kidney cell RNAs were prepared
and assessed at P4 and P15, before and after mutation of the
Trp53 gene and protein. Since the RT-PCR assay did not show
a large increase in the Trp53 mRNA level in the -/- kidney cells,
though the +/+ Trp53 level was down relative to -/-, it is
possible that the mutant p53 protein was stabilized in the -/-
kidney cells. Since the p21 protein was missing in -/- kidney
cells (Figure 2) and its mRNA down (Cdkn1a, Figure 6), it is
likely that the other changes such as up-modulation of Rbl1,
E2f1, possibly Cdk6 and Ccnd1 followed the initial changes in
the p53-p21 axis. We have studied only one +/+ and -/- kidney
cell pair thus far; additional -/- kidney cell lines may follow
different pathways to immortality and resistance to carcinogen-
induced apoptosis.
Interestingly, the E2f1 mRNA level is also up in two of the
MEF late passage -/- cultures. Although p53 is not mutated in
the MEFs, MDM2 is up-regulated and amplified (Figure 1) in
two MEFs at late passage, thus taking a post transcriptional
route to p53 inactivation, and Atm mRNA level is up in the
same two MEF late passage cell lines, suggesting ongoing
DNA damage. In all MEF cell lines at late passage,
transcription of Cdkn2a/p16 is down-regulated, as expected
since this step is likely involved in immortalization.
The in vivo model and the mutator phenotype
To show that the mutator phenotype induced by Fhit loss
(modeled in Figure 10) could also underlie preneoplastic
changes in vivo, we examined carcinogen-induced alterations
in -/- vs +/+ mouse livers. DMBA has been shown to cause
preneoplastic changes in the liver of exposed mice as early as
4 wks after treatment: the mutation frequency after DMBA
treatment was threefold higher in Gadd45a-null liver compared
with wild-type liver [33]; authors concluded that lack of basal
and DMBA-induced Gadd45a may result in enhanced
tumorigenesis because of decreased DNA repair and
increased mutation frequency, contributed by the genomic
instability and loss of normal growth control in cells from
Gadd45a-null mice.
We believe that our exome sequencing data for the kidney
cell DNAs and DNA of livers of DMBA exposed mice can be
similarly interpreted: the livers of the -/- mice with and without
DMBA showed increased numbers of exome mutations relative
to the WT counterpart mouse livers. Interestingly, many of the
-/- exome sequences showed clustered mutations, ie several
mutations clustered in numerous individual genes as illustrated
in Figure S5. This type of clustered mutations and mutation
‘showers’ have recently been shown to be functionally linked
with cancer development through the action of APOBEC
(apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-
like) cytidine deaminases [34,35], especially APOBEC3B. The
mouse genome includes only one APOBEC family member
gene, APOBEC3 and we do not yet know if it is involved in
development of these mutation clusters.
The main purpose of this study was to support the
hypothesis that the Fhit loss-induced genome instability
promotes, under selective conditions, the expansion of Fhit-
deficient clones and the attendant mutations. The in vitro
studies of the MEF and kidney cell lines provide evidence that
Fhit-deficient cells have selective proliferative and survival
advantages and the analysis of exome sequence alterations of
the kidney cell and DMBA exposed liver tissue DNAs of Fhit-
deficient mice showed enhanced mutation frequencies.
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Negrini et al [1] suggested a temporal order by which the
sporadic cancer hallmarks are acquired with deregulation of
growth-regulating genes as the initiating event. In their model
this would lead to DNA damage and DNA replication stress,
which, in turn, would lead to genomic instability and selective
pressure for TP53 inactivation. Then loss of p53 function would
allow evasion of cell death, while the genomic instability would
provide a fertile ground for additional mutations.
The results of our current study suggest that, as in hereditary
cancers and as modeled in Figure 10, genome instability in
sporadic cancers often occurs first due to replication stress at
fragile regions, followed by inactivation of Fhit, that provides
continued mild genome instability, followed by the other events
as in hereditary cancers.
When the Fhit knockout mouse model was first developed
and characterized, there were two noteworthy but unexplained
features early in the study and another that was noted while
tallying spontaneous tumors in mice between 1 and 2 years of
age: first it was clear that carcinogen treatment induced many-
fold more upper gastrointestinal tumors in Fhit-/- than in WT
mice; secondly, some Fhit-/- mice on the mixed 129XB6
background spontaneously developed Muir-Torre-like
sebaceous tumors [11], that had formerly been known to occur
in mismatch repair-deficient cancers. The sebaceous tumors
can now be explained by the absence of the Fhit caretaker
function [36] in the -/- mice and it is likely that the exquisite
sensitivity to carcinogen induction of tumors is also due, in part,
to loss of this function. The third feature, a relatively high rate
of systemic, lethal infections among the -/- mice might [10] also
be due to global genome instability if it causes mistakes in
immunoglobulin or T-cell receptor rearrangements, an
hypothesis not yet explored.
Supporting Information
Figure S1.  Morphology of Fhit+/+ and Fhit-/- kidney-derived
cell clones. (A) Representative micrographs of fixed, crystal
biored stained cell lines cloned from +/+ and -/- kidney cells.
(B) Immunoblots for Fhit and GAPDH expression levels in each
Fhit+/+ cloned cell line.
(TIF)
Figure S2.  Clonogenicity and microscopic observation of
DMBA-treated kidney cells at early and late passage. (A)
Colonies formed by +/+ and -/- mouse kidney cells (P10 and
P21). (B, C) Photographs of +/+ and -/- mouse kidney cells
before and 3 days after 20 µM DMBA treatment for 24 h (B,
P10; C, P21). The cells were examined by light and phase-
contrast microscopy after Senescence ß-gal staining.
(TIF)
Figure S3.  Fhit-/- MEF cells at late passage show
decreased sensitivity to apoptosis. Photographs of MEF+/+
3 and -/- 5 cells (P31) before and 3 days after 20 µM DMBA
treatment for 24 h.
(TIF)
Figure S4.  DMBA -/- kidney cell survivors are resistant to
DMBA-induced senescence. Photographs of -/- DMBA
survivors before, 3 and 7 days after 20 µM DMBA treatment for
24 h. The cells were examined by light and phase-contrast
microscopy after Senescence ßgal staining.
(TIF)
Figure S5.  Frequency of genes with clustered point
mutations in DNAs of mouse kidney cells and liver tissue.
(A) Bar graph representing comparison of numbers of genes
containing clustered point mutations in -/- kidney cells that
survived DMBA treatment vs untreated -/- and +/+ kidney cells,
from exome sequence data. (B) Graphs representing
comparisons of the numbers of genes containing clustered
point mutations in livers of -/- and +/+ mice with and without
DMBA treatment, from exome sequence data. (C) The average
number of genes with clustered mutations in kidney and liver
KO samples (n=6) vs kidney and liver WT samples (n= 4) was
analyzed in a 2-tailed, unpaired Student’s t-test (P=0.000002).
(TIF)
Table S1.  Complete list of copy number variations in Fhit
+/+ and Fhit-/- cells and Fhit-/- mouse tails.
(DOCX)
Table S2.  Detailed changes in expression of the
Senescence Array genes in mouse kidney cells at early
and late passages (related to Figure 6). Changes in gene
expression between +/+ and -/- mouse kidney cells were
determined via relative fold-changes in the mRNA levels
assayed by RT-qPCR amplification. Fold-changes were
calculated by comparing the 2-ΔCt values in +/+ mouse kidney
mRNAs at P4 to +/+ and -/- mouse kidney mRNAs at P15.
Fold-change values >1 indicate positive or up-regulation. Fold-
change values <1 indicate negative or down-regulation. Fold-
changes >2 are indicated in red; fold-change values <0.5 are
indicated in blue.
(XLSX)
Table S3.  Detailed changes in expression of the
Senescence Array genes in MEF cultures at early and late
passages (related to Figure 7). Changes in gene expression
between +/+ and -/- MEF cultures were determined via relative
fold-changes in the mRNAs detected by RT-qPCR assays.
Fold-changes represent a comparison of the 2-ΔCt values for
+/+ MEF mRNA levels at passage 3 with +/+ and -/- MEF
mRNAs at passage 27. As in Table S2 above, fold-change
values >1 indicate positive or up-regulation. Fold-change
values <1 indicate negative or down-regulation.
(XLSX)
Table S4.  Insertions and deletions in the +/+ and -/- mouse
liver DNA, with and without DMBA treatment, related to
Figure 8.
(XLS)
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Table S5.  Insertions and deletions in the -/- mouse kidney
cells after DMBA treatment and after subtraction of indels
common to the exome sequences of the untreated -/-
kidney cells (related to Figure 9).
(XLS)
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